SpectraGenetics specializes in advanced technologies centered around fluorogen-activating proteins (FAPs) and their applications in studying G-protein coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). FAPs are engineered polypeptides that bind to specific organic fluorogen molecules, forming fluorescent complexes that enable the detection and quantification of receptor internalization. This process is particularly useful in live-cell assays, where FAPs are tagged to receptors at their extracellular N-termini. The company has developed proprietary fluorogens that exhibit distinct spectral properties, allowing researchers to differentiate between surface and internalized receptors based on fluorescence signals.

Two notable assays developed by SpectraGenetics are the pHD assay and the SSC assay. The pHD assay utilizes a fluorogen that produces both direct and FRET fluorescence, with the FRET signal being enhanced in acidic environments, thus allowing for real-time quantification of receptor internalization. The SSC assay employs a fluorogen that can be cleaved by a reducing agent, enabling the separation of signals from internalized and surface receptors after cell fixation. These innovative assays, along with a range of FAPs and fluorogens, provide researchers with powerful tools for studying receptor dynamics and cellular responses in various biological contexts.

United States

SpectraGenetics is a GPCR Company with proprietary technology for the direct measurement of GPCR internalization, trafficking and recylcling back to the cell membrane.  This technology does not rely on secondary messengers or require imaging.  It is based on Fluorogen Activating Peptide (FAP)  technology originally developed at Carnegie Mellon University.  The company has tagged more than 150 GPCRs and has validated more than 30 cell lines.

SpectraGenetics

Company Details